Galapagos NV Logo

Galapagos NV

Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.

GLPG | BR

Overview

Corporate Details

ISIN(s):
BE0003818359
LEI:
549300QKJ78IY0IOV655
Country:
Belgium
Address:
Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, 2800 Mechelen
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Galapagos NV is a biotechnology company dedicated to transforming patient outcomes through scientific innovation. Following a strategic restructuring, the company now focuses on developing and commercializing novel cell therapies, particularly in oncology. It leverages a unique, decentralized, and scalable manufacturing platform designed to rapidly deliver CAR-T therapies to patients. Galapagos is actively growing its pipeline through strategic acquisitions and partnerships while seeking to divest its legacy small molecule assets. The company's mission is to develop life-changing treatments to provide patients with more years of life and improved quality of life.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-26 07:30
Investor Presentation
GALAPAGOS_NV_Corp_Structure_TD_14.11.2025.pdf
German 151.3 KB
2025-11-26 07:30
Investor Presentation
GALAPAGOS_NV_Corp_Structure_TD_12.11.2025.pdf
German 151.9 KB
2025-11-26 07:30
Major Shareholding Notification
GALAPAGOS NV Form TD 14.11.2025_Revised Part I.pdf
English 956.3 KB
2025-11-26 07:30
Major Shareholding Notification
GALAPAGOS NV Form TD 12.11.2025_Part I_Revision2.pdf
English 956.0 KB
2025-11-26 07:30
Major Shareholding Notification
Galapagos Receives Transparency Notifications from Bank of America .pdf
English 243.9 KB
2025-11-26 07:30
Major Shareholding Notification
Galapagos ontvangt transparantieverklaringen van Bank of America .pdf
Dutch 283.4 KB
2025-11-05 22:01
Earnings Release
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Upda…
English 465.4 KB
2025-11-05 22:01
Earnings Release
Galapagos rapporteert financiële resultaten over de eerste negen maanden van 20…
Dutch 593.4 KB
2025-10-21 07:30
Regulatory Filings
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the…
English 274.0 KB
2025-10-21 07:30
Regulatory Filings
Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen als onde…
Dutch 288.2 KB
2025-08-08 07:36
Share Issue/Capital Change
Galapagos Creates New Subscription Right Plan
Dutch 203.1 KB
2025-08-08 07:36
Share Issue/Capital Change
Galapagos Creates New Subscription Right Plan
English 201.6 KB
2025-08-07 00:00
Remuneration Information
Galapagos_PR_07082025_ENG.pdf
English 208.3 KB
2025-08-07 00:00
Remuneration Information
Galapagos_PR_07082025_NL.pdf
Dutch 215.6 KB
2025-08-07 00:00
Report Publication Announcement
1. Subscription Right Plan 2025 (B)_Board Report_7_180-7_191_ENG_FINAL_Website(…
English 262.4 KB

Automate Your Workflow. Get a real-time feed of all Galapagos NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Galapagos NV

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Galapagos NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-22 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 58,375 1,681,760.40 USD
2025-05-22 EcoR1 Capital Fund, L.P. Close relation Buy 3,898 112,299.82 USD
2025-05-20 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 14,321 412,553.64 USD
2025-05-20 EcoR1 Capital Fund, L.P. Close relation Buy 956 27,540.07 USD
2025-05-19 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 9,376 261,151.60 USD
2025-05-19 EcoR1 Capital Fund, L.P. Close relation Buy 626 17,436.10 USD
2025-05-16 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 39,112 1,077,934.54 USD
2025-05-16 EcoR1 Capital Fund, L.P. Close relation Buy 2,612 71,987.24 USD
2025-05-15 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 187,480 5,015,090.00 USD
2025-05-15 EcoR1 Capital Fund, L.P. Close relation Buy 12,520 334,910.00 USD

Peer Companies

OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
Onxeo Logo
Developing precision-guided therapeutics using small antibodies for complex diseases.
France
ALONX
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
OPTIBIOTIX HEALTH PLC Logo
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom
OPTI
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel
ORMP
ORASURE TECHNOLOGIES INC Logo
Develops and distributes point-of-care diagnostic tests and sample collection devices.
United States of America
OSUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.